SCHEDULE: Goldman Sachs Discloses 2.7% Stake in Intellia Therapeutics

The Goldman Sachs Group and its subsidiary report a 2.7% passive beneficial ownership in Intellia Therapeutics, Inc. as of December 31, 2025.

Summary

• The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly filed an amendment to Schedule 13G.
• They beneficially own an aggregate of 3,157,178.33 shares of Intellia Therapeutics, Inc. common stock.
• This represents 2.7% of the class of securities.
• The filing indicates shared voting power over 3,156,786.33 shares and shared dispositive power over 3,156,881.33 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a regulatory disclosure of a passive ownership stake by a major financial institution, with no direct positive or negative implications for the issuer's operational performance.

Positives

• Indicates significant institutional interest in Intellia Therapeutics, Inc. from The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.

Negatives

• No specific negative information regarding Intellia Therapeutics, Inc. is disclosed in this beneficial ownership report.

Risks

• No specific risks related to Intellia Therapeutics, Inc. are disclosed in this beneficial ownership report.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding Intellia Therapeutics, Inc.'s future outlook.

Management Comments

• The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Intellia Therapeutics, Inc.

Industry Context

StockSavvy.ai notes that Intellia Therapeutics operates in the biotechnology sector, specifically focusing on CRISPR-based gene editing. A significant passive stake by a major financial institution like Goldman Sachs can signal confidence in the long-term prospects of the company or the broader gene editing industry, which is characterized by high R&D costs and potential for disruptive innovation.

Comparison to Industry Standards

• This filing is a standard disclosure of passive beneficial ownership by a large institutional investor, consistent with regulatory requirements for holdings exceeding certain thresholds.
• The 2.7% stake is below the 5% threshold that would typically trigger a Schedule 13D filing, indicating a passive investment intent.
• Comparable institutional holdings in other biotechnology firms often reflect similar passive investment strategies by large asset managers or broker-dealers.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings involving Intellia Therapeutics, Inc. are disclosed in this filing.

Related Party Transactions

• No related party transactions involving Intellia Therapeutics, Inc. are disclosed in this filing.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially signaling confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this beneficial ownership report.

Next Steps

• Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC will continue to monitor their beneficial ownership in Intellia Therapeutics, Inc.
• Further amendments to Schedule 13G would be filed if there are significant changes in their ownership percentage or investment intent.

Key Dates

Keywords

Intellia Therapeutics, Goldman Sachs, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Gene Editing, CRISPR